

Shinjiro Mori · Yutaka Ogata · Kazuo Shirouzu

Biological features of sporadic colorectal carcinoma with high-frequency microsatellite instability: special reference to tumor proliferation and apoptosis

Received: December 8, 2003 / Accepted: March 18, 2004

Abstract

Background. We evaluated the relationship between biological behavior and microsatellite instability (MSI) status, with or without p53 status, in sporadic colorectal carcinoma.

Methods. MSI was analyzed with regard to biological features such as cellular proliferation and apoptotic cell death, in addition to clinicopathological features, in 87 patients with sporadic colorectal carcinoma.

Results. Fourteen (16.1%) of 87 tumors showed instability at two or more of the five loci examined (high-frequency MSI [MSI-H]). Four demonstrated instability at one locus (low-frequency MSI [MSI-L]), and 69 showed no instability (microsatellite-stable [MSS]). The MSI-H tumors tended to be located in the proximal colon and more often were mucinous carcinoma. The MSI-H tumors also tended to be in patients with multiple colorectal carcinomas and to demonstrate, rarely, an infiltrating growth pattern or venous invasion. The incidence of p53 protein overexpression in the MSI-H tumors was significantly lower than that in the MSI-L/MSS tumors (21% vs 54%). There was no significant difference in the proliferating-cell nuclear antigen (PCNA) labeling index (PI) or apoptotic index (AI) between the MSI-H and MSI-L/MSS tumors. The AI in the MSI-H tumors with p53 overexpression was significantly lower than that in the MSI-H tumors without p53 overexpression, and was also significantly lower than that in the MSI-L/MSS tumors with p53 overexpression. In the MSI-H tumors with p53 overexpression, no expression of BAX protein was found, and there was high expression of bcl-2 protein, resulting in a low BAX/bcl-2 ratio.

Conclusion. In sporadic colorectal carcinoma, an MSI-H tumor with p53 protein overexpression may display aggressive biological features.

Key words Sporadic colorectal carcinoma · Microsatellite instability · Cellular proliferation · Apoptosis · PCNA · p53

Introduction

Two main genetic pathways leading to colorectal adenocarcinoma can be distinguished.^{1,2} Tumors generated by the classic “suppressor” pathway display marked chromosomal instability, with frequent cytogenetic abnormalities and allelic losses.³ The second genetic pathway is involved in the development of tumors in patients with hereditary nonpolyposis colorectal cancer (HNPCC). The hallmark of this alternative “mutator” pathway is widespread microsatellite instability (MSI), which is characterized by an accumulation of somatic alterations in the length of simple, repeated sequences called microsatellites. High-frequency microsatellite instability (MSI-H) results from DNA repair error.^{4,5} The MSI that is typically seen in HNPCC is also reportedly observed in sporadic colorectal carcinoma.⁶ The transforming growth factor (TGF) β receptor type II gene, the insulin-like growth factor II receptor gene, and the *BAX* gene, which encode molecules related to tumor proliferation and apoptosis, have been found to be targets for MSI.^{7–9}

Colorectal adenocarcinomas originating through the suppressor pathway differ in pathological features from those originating through the mutator pathway.^{10,11} Furthermore, patients with an MSI-H tumor have a more favorable survival than patients with low-frequency MSI (MSI-L) or microsatellite-stable (MSS) tumor.^{12–14} However, reasons for the favorable survival in patients with an MSI-H tumor are still unclear. In general, the high mutational load in MSI-H tumors is suspected to be detrimental to their growth and metastatic potential. Thus, biological features related to the functions of the target genes for MSI in sporadic colorectal carcinoma should be particularly evaluated and compared with those in colorectal carcinomas derived from the suppressor pathway.

S. Mori · Y. Ogata (✉) · K. Shirouzu
Department of Surgery, Kurume University School of Medicine,
67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan
Tel. +81-942-31-7566; Fax +81-942-34-0709
e-mail: yogata@med.kurume-u.ac.jp

In the present study, to investigate any correlation between malignant biological behavior and MSI status, we analyzed MSI with regard to biological features such as cellular proliferation and apoptosis, in addition to clinicopathological features. We also discuss the prognosis of patients with sporadic colorectal carcinoma according to MSI status. We demonstrated a significant relationship between MSI status, combined with p53 protein expression status, and apoptosis in sporadic colorectal carcinoma, using immunohistochemical techniques and terminal deoxy-nucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) staining.

Patients and methods

Patients and specimens

A total of 87 patients with sporadic colorectal carcinomas who underwent surgery between 1995 and 1998 at Kurume University Hospital were reviewed. The tumors were defined as sporadic colorectal carcinoma by excluding familial adenomatous polyposis and HNPCC according to the Amsterdam criteria II.¹⁵ The patients had had no preoperative chemotherapy or radiation therapy. Fresh surgical specimens and formalin-fixed specimens were used for MSI analysis, histopathological examination, immunostaining, and TUNEL staining. Fifty-five patients were male, and 32 were female. The patients ranged in age from 38 to 86 years, and their average age was 63.8 ± 10.5 years. The series consisted of 23 patients with cancer in the proximal colon, 35 patients with cancer in the distal colon, and 29 patients with rectal cancer. Pathological factors and staging for colorectal cancer were defined according to the International Union Against Cancer TNM classification.¹⁶ The grading of lymphatic permeation and venous invasion was defined according to our previous reports.^{17,18}

Follow-up investigations were performed through outpatient visits, by letter, or by telephone, and the most recent date of contact for each patient was regarded as the final date of survival. The maximum patient follow-up period was 78 months, and the mean follow-up period was 38 months.

MSI analysis

Representative tumor samples and fragments of corresponding normal mucosa were obtained from fresh surgical specimens, and stored in liquid nitrogen until DNA extraction. Genomic DNA was extracted from tissue using a standard phenol-chloroform procedure.¹⁹ For MSI evaluation, we amplified five microsatellite regions, using the following primer sets: for the short arm of chromosome 2 (*D2S123*), for the short arm of chromosome 3 (*D3S1067*), for the short arm of chromosome 17 (*TP53*), for the long arm of chromosome 18 (*D18S51*), and for the short arm of chromosome

(*BAT26*). These primers were obtained with a 380A DNA synthesizer (Applied Biosystems; Perkin-Elmer, Foster City, CA, USA), using a previously described protocol.²⁰ We developed a simple method, using fluorescence-based polymerase chain reaction (PCR) with an autosequencer for amplification of the five microsatellite loci. The PCR reaction was performed in one tube, using a RoboCycler 40 PCR machine (Stratagene, La Jolla, CA, USA) over 29 cycles with 0.2–1 μ l of primers and a Gene Amp kit (Roche Molecular Systems, Branchburg, NJ, USA) under the conditions recommended by the kit supplier. In brief, we used a 50- μ l aliquot containing 100 ng of DNA, 10 mM Tris-HCl (pH 8.3), 75 mM KCl, and 1.5 mM MgCl₂. PCR products were denatured for 5 min at 95°C in formamide dye, and electrophoresed in a 5% polyacrylamide gel containing 6 M urea, using a PRISM377 DNA sequencer (Applied Biosystems; Perkin-Elmer). The electrophoresis was performed using Tris-Borate-EDTA (TBE) buffer at 3000 V, and the interval time to collect fluorescence signals on the autosequencer was 2400 scans per hour.

The MSIs of the five genes were assessed. In principle, detection of PCR product peaks was performed using Gene Scan software²¹ (Applied Biosystems). When PCR products of abnormal size or novel alleles compared with corresponding normal tissue were recognized, the genes were defined as showing MSI. Tumors exhibiting MSI with at least two of the five microsatellite markers were classified as MSI-H.²² Tumors demonstrating instability at a single locus were classified as MSI-L, and tumors without instability at any of the five loci examined were classified as MSS.²² In all the analyses associated with MSI, MSI-L and MSS tumors were grouped together and are indicated as MSI-L/MSS.

Immunostaining

Immunohistochemical staining was performed using a labeled streptavidin-biotin technique (SLAB kit: DAKO Cytomation, Carpinteria, CA, USA) on 4- μ m thick, formalin-fixed, and paraffin-embedded sections. In brief, after deparaffinization, the sections were autoclaved at 120°C for 10 min in citrate buffer. Nonspecific binding activity was inhibited with blocking serum at room temperature for 20 min. Sections were then incubated with primary monoclonal antibody against p53 (DO7; DAKO Cytomation, Glostrup, Denmark), diluted at 1:50; monoclonal antibody against p21 (WAF1; Novocastra Laboratories, Newcastle, UK), diluted at 1:30; monoclonal antibody against proliferating-cell nuclear antigen (PCNA) (PC-10; DAKO Cytomation, Glostrup, Denmark); monoclonal antibody against BAX (Anti-BAX; Upstate, Waltham, NY, USA); and monoclonal antibody against bcl-2 (clone124; DAKO Cytomation) at 4°C overnight, respectively, followed by incubation with biotinylated link antibody and peroxidase-labeled streptavidin at room temperature for 20 min. Staining was detected using 3-amino-9-ethylcarbazol (DAKO Cytomation, Carpinteria, CA, USA) for p53 and 3',3'-diaminobenzidine (DAKO Cytomation, Carpinteria, CA,

USA) for p21, and then counterstaining was done with hematoxylin.

Labeling of apoptotic cells by TUNEL assay

TUNEL staining allows the in-situ detection of apoptotic cells. After deparaffinization and rehydration, the tissue sections were incubated in 20 µg/ml of proteinase K for 15 min at room temperature. After a rinsing in phosphate-buffered saline (PBS) for 5 min, endogenous peroxidase activity was blocked by incubating the sections in 2% H₂O₂ for 5 min at room temperature. Following the rinsing in PBS, the slides were covered with equilibration buffer (ApoTag Plus in situ apoptosis detection kit; Serologicals, Norcross, GA, USA), and incubated for 15 min at room temperature. Apoptotic cells were then identified using an immunoperoxidase detection system.

Statistical analysis

Differences in distributions between the different variables were calculated by the χ^2 test or Fisher's exact test when appropriate. In comparisons with continuous distribution, a two-sample *t*-test was used. Survival rates based on the MSI status were calculated using the Kaplan-Meier method. Comparison of the survival rates was performed using the log-rank test.

Results

MSI status

A tumor was classified as MSI-H when instability at two or more microsatellite loci was detected (more than or equal to 40%). Fourteen (16.1%) of the 87 tumors were classified as MSI-H. Of these 14 MSI-H tumors, 1 displayed instability with all five microsatellite markers, 2 displayed instability with four microsatellite markers, 2 displayed instability with three microsatellite markers, and 9 displayed instability with two microsatellite markers. Four tumors (4.6%) demonstrated instability at one locus (MSI-L), and 69 (79.3%) showed no instability at any of the five loci examined (MSS). The *BAT26* marker exhibited MSI in 14 (100%) of the 14 MSI-H tumors.

Clinicopathological features according to MSI status

Correlations between MSI status and clinicopathological factors are summarized in Table 1. The incidence (43%) of a proximal colon tumor in MSI-H cases was higher than that (23%) in MSI-L/MSS cases. The incidence (29%) of mucinous adenocarcinoma in MSI-H cases was higher than that (3%) in MSI-L/MSS cases. The MSI-H cancers had a significantly higher incidence (21%) of multiple colorectal cancers (synchronous, 2 cases; metachronous, 1 case). MSI-H tumors rarely demonstrated an infiltrating growth pat-

tern or severe venous invasion, although these differences from MSI-L/MSS were not significant. There was no difference in age, sex, tumor infiltration, lymphatic invasion, or lymph node involvement between the patients according to MSI status.

The cumulative 5-year-survival rates of patients with MSI-H tumors and MSI-L/MSS tumors were 82% and 62%, respectively, but the difference did not reach significance (Fig. 1).

The incidence of p53 and p21 immunoperoxidation according to MSI status

Immunostaining of p53 was observed in the tumor cell nuclei (Fig. 2a). When p53 staining was seen in 10% or more tumor cells, the case was defined as positive for p53,¹² in consideration of what was shown to correlate closely with p53 mutation. Positivity of p53 protein expression was seen in 49% of the patients (42 of 86). Immunoreactivity for p21 was also detected in the tumor cell nuclei (Fig. 2b). When positive tumor staining for p21 was seen in 10% or more tumor cells, the case was considered as positive for p21. Positivity of p21 protein expression was seen in 28% of the patients (24 of 86). Positivity of p53 protein expression in MSI-H tumors was 21.4% (3 of 14); this was significantly lower than that (54.1%; 39 of 72) in MSI-L/MSS tumors. No significant difference in the incidence of p21 protein overexpression was found between the MSI-H and MSI-L/MSS tumors (35.7% vs 26.4%). When the tumors were classified according to both the MSI status and p53 protein expression, 39, 33, 11, and 3 tumors were defined as MSI-L/MSS and p53-positive, MSI-L/MSS and p53-negative, MSI-H and p53-negative, and MSI-H and p53-positive, respectively.




Fig. 1. Survival curves according to microsatellite instability MSI status. Cumulative survival curves of the patients with high-frequency MSI (*MSI-H*) and low-frequency MSI/microsatellite stable (*MSI-L/MSS*) tumors were prepared using the Kaplan-Meier method. Statistical comparison was performed using the log-rank test

Table 1. Clinicopathological factors and MSI status

Clinicopathological factors	MSI-H (%)	MSI-L/MSS (%)	<i>P</i> value
Age (mean \pm SD)	63.6 \pm 10.7	63.8 \pm 10.5	0.935
Tumor size (mm; mean \pm SD)	58.4 \pm 27.1	51.9 \pm 20.9	0.309
Sex			0.239
Male	11 (79)	44 (60)	
Female	3 (21)	29 (40)	
Location			0.063
Proximal colon	6 (43)	17 (23)	
Distal colon	7 (50)	28 (38)	
Rectum	1 (7)	28 (38)	
Histological type			0.012
Well	6 (43)	39 (53)	
Mod	4 (29)	26 (36)	
Por	0	5 (7)	
Muc	4 (29)	2 (3)	
pT-factor			0.451
pT1-2	1 (7)	13 (18)	
pT3-4	13 (93)	60 (82)	
pN-factor			0.799
pN0	6 (43)	34 (47)	
pN1-2	8 (57)	39 (53)	
M-factor			0.535
M0	11 (79)	49 (67)	
M1	3 (21)	24 (33)	
Grade of lymphatic permeation ¹⁶			0.766
ly 0-1	10 (71)	48 (66)	
ly 2-3	4 (29)	25 (34)	
Grade of venous invasion ¹⁷			0.128
v 0-1	12 (86)	46 (63)	
v 2-3	2 (14)	27 (37)	
Growth pattern			0.044
Expanding type	10 (71)	31 (42)	
Infiltrating type	4 (29)	42 (58)	
Multiple cancer			0.028
Negative	11 (79)	71 (97)	
Positive	3 (21)	2 (3)	

well, well-differentiated adenocarcinoma; mod, moderately differentiated adenocarcinoma; por, poorly differentiated adenocarcinoma; muc, mucinous adenocarcinoma; MSI, microsatellite instability; MSI-H, high-frequency MSI; MSI-L, low-frequency MSI; MSS, microsatellite stable

PCNA labeling index (PI) and apoptosis index (AI) according to MSI status

The PI was scored as the fraction of positively stained tumor cell nuclei among 500 to 1000 tumor cells (Fig. 2d). The PI of 87 patients available for PCNA scoring was 57.0 ± 1.6 . On the other hand, apoptotic tumor cells were scattered in the tumor tissues (Fig. 2c). The AI was scored as the mean value of apoptotic tumor cells per one field under $200\times$ light microscopy in five random fields. The AI of 87 patients available was 2.18 ± 0.25 .

There was no significant difference in PI or AI between the MSI-H and MSI-L/MSS tumors. When compared in combination with p53 protein status, the AI in the MSI-H tumors with p53 protein overexpression was significantly lower than that in the MSI-H tumors without p53 protein overexpression as well as being significantly lower than that in the MSI-L/MSS tumors with p53 protein overexpression. No difference in PI was found according to the combined status of p53 expression and MSI (Table 2).

Immunoexpression of BAX and bcl-2 according to MSI status

Both BAX and bcl-2 protein were expressed in the cytoplasm of the tumor cells (Fig. 2e,f). When positive staining of BAX and bcl-2 occurred in more than 10% of tumor cells, the case was considered as positive for BAX and bcl-2. The positive ratios for BAX and bcl-2 expression were compared according to MSI status. The ratio of BAX expression in the MSI-H tumors appeared to be lower than that in the MSI-L/MSS tumors, although the difference did not reach significance. The positive ratio of BAX expression was stratified according to the combined status of MSI and p53 protein expression. No BAX expression was found in the MSI-H tumors with p53 protein overexpression; the incidence of BAX expression was 45% in the MSI-H tumors without p53 overexpression, 62% in the MSI-L/MSS tumors with p53 overexpression, and 67% in the MSI-L/MSS tumors without p53 overexpression, with no significant differences seen between these groups. When the tumors were classified into three groups and scored 1 to 3 for the concomitant expression of bcl-2 and BAX (score 1, bcl-2-positive and BAX-negative; score 2, bcl-2-positive and




Fig. 2a–f. Immunostaining and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL) staining. Immunostaining for p53, p21, proliferating-cell nuclear antigen (PCNA), BAX, and bcl-2, and TUNEL staining, were performed as described in “Materials and methods”. **a** Nuclear staining of p53, **b** p21, and **d**

PCNA, and **e** cytoplasmic staining of BAX and **f** bcl-2 were observed. p53 and p21 expressions tended to differ at the cellular level. **c** Apoptotic cells detected by TUNEL staining were scattered. **a, b** $\times 40$; **d, e, f** $\times 100$; **c** $\times 200$

BAX-negative; score 3, bcl-2-negative and BAX-positive), the score in the MSI-H tumors with p53 overexpression was significantly lower than that in the MSI-L/MSS tumors with p53 overexpression or that in the MSI-L/MSS tumors without p53 overexpression (Table 3).

Discussion

An international workshop in Bethesda, Maryland, sponsored by the National Cancer Institute, has formulated guidelines for the evaluation of MSI in colorectal carci-

Table 2. Apoptosis index (AI) and PCNA labeling index (PI) in colorectal cancer tissues

Category	Number	AI (mean ± SE)	P value	PI (mean ± SE)	P value
MSI			0.327		0.347
MSI-L/MSS	n = 73	2.39 ± 0.24		56.8 ± 1.6	
MSI-H	n = 14	1.84 ± 0.33		60.6 ± 3.7	
MSI and p53					
MSI-L/MSS, 0p53(-)	n = 33	2.35 ± 0.42	0.167*	55.5 ± 2.4	0.345*
MSI-L/MSS, p53(+)	n = 39	2.43 ± 0.27	0.042*	57.9 ± 2.2	0.512*
MSI-H, p53(-)	n = 11	2.24 ± 0.32	0.012*	59.9 ± 4.6	0.720*
MSI-H, p53(+)	n = 3	0.37 ± 0.12		63.4 ± 5.8	
MSI and p21					
MSI-L/MSS, p21(-)	n = 52	2.26 ± 0.23	0.103**	55.4 ± 2.0	0.724**
MSI-L/MSS, p21(+)	n = 19	2.67 ± 0.65	0.177*	60.5 ± 3.0	0.572**
MSI-H, p21(-)	n = 9	1.30 ± 0.37		57.2 ± 5.4	
MSI-H, p21(+)	n = 5	2.80 ± 0.34	0.021**	66.8 ± 2.5	0.234**

* Compared with MSI-H, p53(+); ** compared with MSI-H, p21(-)
PCNA, proliferating-cell nuclear antigen

Table 3. Positivity of BAX and bcl-2 protein expression and the concomitant expression score

Category	Number	BAX (%)	P value	bcl-2 (%)	P value	CES (mean ± SE)	P value
MSI			0.072		0.775		0.015
MSI-L/MSS	n = 73	64.4		48.6		2.39 ± 0.07	
MSI-H	n = 14	35.7		42.9		1.93 ± 0.20	
MSI and p53			0.109		0.377		
MSI-L/MSS, p53(-)	n = 33	66.7		39.4		2.39 ± 0.11	0.007*
MSI-L/MSS, p53(+)	n = 39	61.5		53.7		2.39 ± 0.10	0.008*
MSI-H, p53(-)	n = 11	45.5		36.4		2.09 ± 0.21	0.114*
MSI-H, p53(+)	n = 3	0		66.7		1.33 ± 0.33	

* compared with MSI-H, p53(+)
CES, concomitant expression score

noma.²² According to the recommendations endorsed at the workshop, a minimum of five markers should be employed to assess MSI in these tumors. Furthermore, a panel of five microsatellites has been validated as a reference panel, and several alternative loci of established utility have also been indicated. When the tumors in our study were classified as MSI-H tumors and MSI-L/MSS tumors according to the criteria, the incidence of MSI-H tumors in sporadic colorectal carcinomas was 16%. This value is similar to that in previous studies.^{12,13}

It has been reported that MSI-H colorectal tumors differ from MSI-L/MSS tumors in several pathological features. In agreement with most previous investigations,¹⁰⁻¹² we found that MSI-H tumors tended to be located in the proximal colon and were more often mucinous carcinoma than MSI-L/MSS tumors. The MSI-H tumors also tended to be in patients with multiple colorectal carcinomas and to, rarely, demonstrate an infiltrating growth pattern or venous invasion.

The survival rate in the patients with MSI-H tumors tended to be higher than that in patients with MSI-L/MSS tumors. Previous studies in large numbers of patients have shown a more favorable prognosis for patients with MSI-H colorectal carcinomas. However, the biological basis of the more favorable clinical course of patients with MSI-H colorectal carcinoma is still undetermined. As a suggested reason for the favorable outcome, it has been reported that the high mutational load in MSI-H tumors elicited a strong

host immune response arising as a result of a high mutation rate in tumor-associated antigens.^{23,24} In fact, intense lymphocytic infiltration and conspicuous Crohn-like lymphoid reaction in tumor tissues are significantly associated with MSI-H tumors.¹² It has also been indicated that diploid nuclear DNA content, determined using flow cytometry, and low rates of loss of heterozygosity in *DCC/18q*, *p53/17p*, and *K-ras* mutations represented relevant biological characteristics of MSI-H colorectal carcinomas.^{25,26} In other words, tumors derived via the “suppressor” pathway, most of which display MSI-L/MSS, are thought to have more frequent cytogenetic abnormalities related to tumor growth and metastasis than tumors derived via the “mutator” pathway.

With regard to tumor cell proliferation, wild p53 protein has been implicated in controlling checkpoints during the G1 phase of the cell cycle that may monitor the state of the DNA before entry into the S phase.²⁷ Following DNA damage, p53 protein levels rise dramatically, and the p53 induces p21 protein,²⁸ which causes G1 growth arrest through inhibition of cyclin-dependent kinase,^{29,30} and the entry into the S phase is delayed until the genomic lesions are fully repaired. Otherwise, p53 protein inhibits bcl-2 protein expression and induces BAX protein expression, leading to cell apoptosis.³¹ When p53 function is lost, tumor cells enter the S phase without appropriate DNA repair or induction of apoptosis, leading to fixation and propagation of genetic alterations.²⁷ Our immunohistochemical results

showed a significantly higher incidence of abnormal p53 protein accumulation in the MSI-L/MSS tumors compared with the MSI-H tumors, as has been reported previously.^{12,32,33} Because MSI-L/MSS tumors derived via the “suppressor” pathway have a high incidence of mutation of the *p53* suppressor gene, the tumors are thought to have aggressive biological features related to tumor proliferation and apoptosis. On the other hand, because the TGF β type II receptor gene, the insulin-like growth factor II receptor gene, and the *BAX* gene are targets for MSI,⁷⁻⁹ we have proposed that MSI-H tumors also have a high activity of tumor proliferation and a low activity of apoptosis induction.

Our question is how the target genes for MSI, such as the TGF β type II receptor gene and the *BAX* gene, contribute to the determination of tumor biological activity in sporadic colorectal carcinomas. In our results, although there was no difference in AI or PI according to MSI status, the AI in MSI-H tumors with p53 protein overexpression was significantly lower than that in the MSI-H tumors without p53 protein overexpression, as well as being significantly lower than that in the MSI-L/MSS tumors with p53 protein overexpression. This result was explained by the concomitant expression of *bcl-2* and *BAX* protein in the tumors (these being negative and positive regulators of apoptosis, respectively). Namely, in the MSI-H tumors with p53 protein overexpression, no expression of *BAX* protein was found and there was high expression of *bcl-2* protein, resulting in a low *BAX/bcl-2* ratio. The *BAX/bcl-2* ratio is reportedly a good indicator of apoptosis.³⁴ In general, *p53* gene mutations, were identified in MSI-L/MSS tumors. Unexpectedly, *p53* gene mutations were identified in a distinct substantial subset of MSI-H tumors.³⁵ Our results suggested that, in MSI-H tumors with *p53* mutation, tumor apoptosis may be strongly inhibited by alterations of related genes which resulted from both MSI and p53 dysfunction. Eshleman et al.³⁵ reported that MSI-H cell lines bearing mutant *p53* demonstrated the same stability of chromosome number, and the same stability of chromosome structure, as MSI-H cell lines with wild-type *p53*. It is suggested that the apparent chromosomal stability in MSI-H sporadic colorectal carcinomas is a consequence of the presence of wild-type *p53* alleles; otherwise, mutation on the *p53* gene in MSI-H tumors may occur accidentally in a different manner from that in the “suppressor” pathway.

In conclusion, from the aspect of tumor growth activity, we could not find a reason for the favorable outcome in patients with an MSI-H tumor compared to those with an MSI-L/MSS tumor. However, in MSI-H tumors with p53 protein overexpression, genes such as *BAX* and *bcl-2* may be directly affected by the loss of p53 function and by a high mutational load of MSI-H, resulting in potentially high activity of tumor growth. There is a possibility that patients having an MSI-H tumor with p53 protein overexpression may show a poorer prognosis compared to those having an MSI-H tumor with wild-type *p53*. Unfortunately, we could not reach a conclusion on this point in the present study because of the small number of samples. In the future, studies using large sample numbers should confirm that our

data are reproducible, and whether or not the prognosis of patients having an MSI-H tumor with *p53* mutation is poor compared to prognosis in the other subsets.

Acknowledgments This work was supported by a Grant-in-Aid for Scientific Research (C) from The Ministry of Education, Science, Sports, and Culture of Japan (No. 10671231).

References

1. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. *Cell* 87:159–170
2. Toft NJ, Arends MJ (1998) DNA mismatch repair and colorectal cancer. *J Pathol* 185:123–129
3. Lengauer C, Kinzler KW, Vogelstein B (1997) Genetic instability in colorectal cancers. *Nature* 386:623–627
4. Chung DC, Rustgi AK (1995) DNA mismatch repair and cancer. *Gastroenterology* 109:1685–1699
5. Rhyu MS (1996) Molecular mechanisms underlying hereditary nonpolyposis colorectal carcinoma. *J Natl Cancer Inst* 88:240–251
6. Vogelstein B, Fearon ER, Hamilton SR, et al. (1988) Genetic alterations during colorectal-tumor development. *N Engl J Med* 319:525–532
7. Parsons R, Myeroff LL, Liu B, et al. (1995) Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. *Cancer Res* 55:5548–5550
8. Souza RF, Appel R, Yin J, et al. (1996) Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. *Nat Genet* 14:255–257
9. Rampino N, Yamamoto H, Ionov Y, et al. (1997) Somatic frame-shift mutations in the *BAX* gene in colon cancers of the microsatellite mutator phenotype. *Science* 275:967–969
10. Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. *Science* 260:816–819
11. Jass JR, Do KA, Simms LA, et al. (1998) Morphology of sporadic colorectal cancer with DNA replication errors. *Gut* 42:673–679
12. Gafa R, Maestri I, Matteuzzi M, et al. (2000) Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. *Cancer* 89:2025–2037
13. Wright CM, Dent OF, Barker M, et al. (2000) Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. *Br J Surg* 87:1197–1202
14. Halling KC, French AJ, McDonnell SK, et al. (1999) Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. *J Natl Cancer Inst* 91:1295–1303
15. Vasen HF, Watson P, Mecklin JP, et al. (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology* 116:1453–1456
16. Sobin LH, Wittekind C (1997) UICC TNM classification of malignant tumours, 5th edn. John Wiley and Sons, New York
17. Shirouzu K, Isomoto H, Morodomi T, et al. (1995) Carcinomatous lymphatic permeation. Prognostic significance in patients with rectal carcinoma – a long term prospective study. *Cancer* 75:4–10
18. Shirouzu K, Isomoto H, Kakegawa T, et al. (1991) A prospective clinicopathologic study of venous invasion in colorectal cancer. *Am J Surg* 162:216–222
19. Naidoo R, Tarin M, Reddi A, et al. (1999) Allelic imbalance and microsatellite instability in chromosomes 2p, 3p, 5q, and 18q in esophageal squamous carcinoma in patients from South Africa. *Diagn Mol Pathol* 8:131–137
20. Schott ME (1985) A simple manual method for oligonucleotide synthesis. *Am Biotechnol Lab* 3:20–23
21. Kinoshita M, Nakamura J, Kusaka H, et al. (1999) Automated and simultaneous identification of microsatellite instability by fluorescence-based polymerase chain reaction (PCR) in four loci. *Clin Chem Acta* 279:15–23
22. Boland CR, Thibodeau SN, Hamilton SR, et al. (1998) A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* 58:5248–5257

23. Bustin SA, Li SR, Phillips S, et al. (2001) Expression of HLA class II in colorectal cancer: evidence for enhanced immunogenicity of microsatellite-instability-positive tumours. *Tumor Biol* 22:294–298
24. Guidoboni M, Gafa R, Viel A, et al. (2001) Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. *Am J Pathol* 159:297–304
25. Forster S, Sattler HP, Hack M, et al. (1998) Microsatellite instability in sporadic carcinomas of the proximal colon: association with diploid DNA content, negative protein expression of p53, and distinct histomorphologic features. *Surgery* 123:13–18
26. Jass JR, Biden KG, Cummings MC, et al. (1999) Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathway. *J Clin Pathol* 52:455–460
27. Lane DP (1992) Cancer p53, the guardian of the genome. *Nature* 358:15–16
28. El-Deiry W, Tokino T, Velculescu VE, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. *Cell* 75:817–825
29. Harper JW, Adami GR, Wei N, et al. (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. *Cell* 75:805–816
30. Xiong Y, Hannon GJ, Zhang H, et al. (1993) p21 is a universal inhibitor of cyclin kinases. *Nature* 366:701–704
31. Miyashita T, Krajewski S, Krajewska M, et al. (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. *Oncogene* 9:1799–1805
32. Muta H, Noguchi M, Perucho M, et al. (1996) Clinical implications of microsatellite instability in colorectal cancers. *Cancer* 77:265–270
33. Fujiwara T, Stolker JM, Watanabe T, et al. (1998) Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. *Am J Pathol* 153:1063–1078
34. Chresta CM, Masters JR, Hickman JA (1996) Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax: Bcl-2 ratio. *Cancer Res* 56:1834–1841
35. Eshleman JR, Casey G, Kochera ME, et al. (1998) Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53. *Oncogene* 17:719–725